Inhibrx LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Inhibrx LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH359421D
  • |
  • Pages: 20
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Inhibrx LP (Inhibrx) is a biotherapeutic company that develops drugs for treatment of oncology, infectious disease and inflammatory diseases. The company's products include therapeutic proteins with multivalent and multi specific molecules which are designed from their antibody technology. Its programs are based on comprehensive target discovery and selection expertise with its creative implementation for therapeutic research. The company's proprietary platforms enable fit-for-function biotherapeutics that interface with the biology of each target antigen and focus immune activation and mediate enhanced signalling. It also develops proprietary discovery and optimization platforms for conventional and single domain antibodies. Inhibrx is headquartered in La Jolla, California, the US.

Inhibrx LP-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Inhibrx LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9

Inhibrx LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Inhibrx LP, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Inhibrx Raises USD410 Million in Venture Financing 11

Inhibrx Secures USD20 Million from Oxford Finance 12

Partnerships 13

Inhibrx and Alpha-1 Project Enter into Agreement 13

Licensing Agreements 14

Inhibrx Enters into Licensing Agreement with Celgene 14

Equity Offering 15

Inhibrx to Raise Funds through Private Placement of Shares 15

Inhibrx LP-Key Competitors 16

Inhibrx LP-Key Employees 17

Inhibrx LP-Locations And Subsidiaries 18

Head Office 18

Recent Developments 19

Clinical Trials 19

Oct 31, 2017: Inhibrx Wins CARB-X Award Of Up To USD 6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections 19

Appendix 20

Methodology 20

About GlobalData 20

Contact Us 20

Disclaimer 20

List of Figures

Inhibrx LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Inhibrx LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Inhibrx LP, Pharmaceuticals & Healthcare, Key Facts 2

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Inhibrx LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Inhibrx LP, Deals By Therapy Area, 2012 to YTD 2018 8

Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9

Inhibrx LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Inhibrx Raises USD410 Million in Venture Financing 11

Inhibrx Secures USD20 Million from Oxford Finance 12

Inhibrx and Alpha-1 Project Enter into Agreement 13

Inhibrx Enters into Licensing Agreement with Celgene 14

Inhibrx to Raise Funds through Private Placement of Shares 15

Inhibrx LP, Key Competitors 16

Inhibrx LP, Key Employees 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Inhibrx LP, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18445
Site License
USD 500 INR 36890
Corporate User License
USD 750 INR 55335

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com